Vanda Pharmaceuticals (VNDA) –
-
Vanda Pharmaceuticals (VNDA) Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ
-
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
-
Increasing unusual call option volume: MAXN VNDA TRV HIG IBKR LYV
-
Form 8-A12B Vanda Pharmaceuticals
-
Form 8-K Vanda Pharmaceuticals For: Apr 17
-
Vanda Pharmaceuticals (VNDA) Adopts Limited Duration Stockholder Rights Plan
-
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
-
Vanda Pharmaceuticals (VNDA) Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
-
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
-
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals (VNDA) for $7.25-$7.75/sh Cash
-
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
-
Form 8-K Vanda Pharmaceuticals For: Apr 02
-
Vanda Pharmaceuticals (VNDA) call put ratio 5.1 calls to 1 put with focus on April 4 and 5 calls
-
Vanda Pharmaceuticals' (VNDA) Fanapt Granted FDA Approval for the Acute Treatment of Bipolar I Disorder
-
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
-
Form 8-K Vanda Pharmaceuticals For: Mar 06
-
Form 4 Vanda Pharmaceuticals For: Mar 04 Filed by: Williams Timothy
-
Form 4 Vanda Pharmaceuticals For: Mar 04 Filed by: Wijkstrom Joakim
-
Form 4 Vanda Pharmaceuticals For: Mar 04 Filed by: Polymeropoulos Mihael Hristos
-
Form 4 Vanda Pharmaceuticals For: Mar 04 Filed by: Moran Kevin Patrick
-
Form 4 Vanda Pharmaceuticals For: Mar 04 Filed by: Birznieks Gunther
-
Vanda Pharmaceuticals (VNDA) Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
-
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
-
Form 144 Vanda Pharmaceuticals Filed by: Williams Timothy
-
Form 144 Vanda Pharmaceuticals Filed by: Wijkstrom Joakim
-
Form 144 Vanda Pharmaceuticals Filed by: Polymeropoulos Mihael Hristos
-
Form 144 Vanda Pharmaceuticals Filed by: Moran Kevin Patrick
-
Form 144 Vanda Pharmaceuticals Filed by: Birznieks Gunther
-
Form 4 Vanda Pharmaceuticals For: Feb 16 Filed by: Williams Timothy
-
Form 4 Vanda Pharmaceuticals For: Feb 16 Filed by: Wijkstrom Joakim
-
Form 4 Vanda Pharmaceuticals For: Feb 16 Filed by: Moran Kevin Patrick
-
Form 4 Vanda Pharmaceuticals For: Feb 16 Filed by: Polymeropoulos Mihael Hristos
-
Form 4 Vanda Pharmaceuticals For: Feb 16 Filed by: Birznieks Gunther
-
Form 8-K Vanda Pharmaceuticals For: Feb 16
-
Form 8-K/A Vanda Pharmaceuticals For: Dec 07
-
Form SC 13G/A Vanda Pharmaceuticals Filed by: VANGUARD GROUP INC
-
Form SC 13G/A Vanda Pharmaceuticals Filed by: RENAISSANCE TECHNOLOGIES LLC
-
Form SC 13G/A Vanda Pharmaceuticals Filed by: DIMENSIONAL FUND ADVISORS LP
-
Form 10-K Vanda Pharmaceuticals For: Dec 31
-
Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 5c
-
Form 8-K Vanda Pharmaceuticals For: Feb 07
-
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
Form 8-K Vanda Pharmaceuticals For: Feb 05
-
Vanda Pharmaceuticals (VNDA) Announces FDA Update for supplemental NDA for HETLIOZ in the Treatment of Insomnia
-
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
-
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
-
Vanda Pharmaceuticals (VNDA) Receives FDA Approval to Proceed with Investigational New Drug VTR-297
-
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
-
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
-
Vanda Pharmaceuticals (VNDA) Announces Court Ordered FDA to Resolve Jet Lag Hearing Request by March 5, 2024
Back to VNDA Stock Lookup
